Dartmouth-based drug discovery company IMV has announced that its lead compound, known as maveropepimut-S, will be trialed in patients with hormone receptor positive/HER2-negative breast cancer.
In a statement, the company said these tumors represent an unmet clinical need with relatively poor responses to preliminary hormonal treatment. The investigator-initiated clinical study will be conducted at the Providence Cancer Institute in Portland, Oregon, and is expected to begin this summer.
“We are excited to launch the next clinical proof of concept study of maveropepimut-S, which has